QuidelOrtho Corporation QDEL

QuidelOrtho (QDEL) is named a stock to sell due to weak constant-currency growth over two years, eroding returns on capital from a low base, and looming cash depletion that could trigger shareholder dilution. At about $10.65 and 13.3x forward P/E, the company—born from the 2022 merger of Quidel and Ortho Clinical Diagnostics—faces risk that recent investments are destroying value and may necessitate fundraising. In contrast, Insulet (PODD) and Eli Lilly (LLY) are highlighted as buys, with PODD delivering 26.7% constant-currency growth over two years, a expanding free cash flow margin, and rising ROIC; LLY showing 43.1% revenue growth and active share repurchases. The piece notes healthcare stocks’ strong rally—up ~38% over six months versus the S&P 500's ~16.9%—and cautions sector regulation could alter outcomes. Weak growth, eroding ROIC, and cash-dilution risk for QDEL imply a meaningful but not catastrophic negative path.

QuidelOrtho releases Episode 61 of Science Bytes focused on sepsis in the emergency department, highlighting early diagnostic strategies to reduce mortality. Sepsis remains a leading cause of death in the U.S.; barriers to diagnosis drive organ failure and higher mortality. Episode 61 features Chris Sanchez, MSN, RN, Medical Science Liaison, who describes diagnostic approaches to support critically ill patients and shares frontline experience. Key insights: about 20% of adults and 10% of children with sepsis die or enter hospice; delayed diagnosis and overuse of fluid resuscitation increase mortality; distinguishing bacterial versus viral infections remains a diagnostic hurdle; unrecognized bacterial infections can quickly escalate to sepsis; rapid diagnosis enables timely intervention and targeted therapy. Serial procalcitonin testing helps clinicians identify opportunities to discontinue or de-escalate antibiotics; early testing supports quick, targeted treatment decisions in the ER. Available on major platforms and at QuidelOrtho's site. Emphasizes rapid diagnostic strategies in sepsis care, potentially affecting perception of QuidelOrtho's diagnostic leadership without current product or revenue milestones.

QuidelOrtho cut its 2026 outlook, intensifying concerns over China exposure and respiratory segment risks. Outlook reduction signals major risks in key markets that will likely alter performance trajectory and investor views.

QuidelOrtho cut its 2026 revenue outlook while reporting narrower losses, driving a 6% stock increase. Lowered 2026 revenue guidance introduces moderate long-term growth concerns offset by short-term profitability gains.

QuidelOrtho faces China-related risks that may pressure performance, yet its core growth stays resilient, leaving open the question of whether the stock is worth buying. China exposure introduces moderate revenue and sentiment risks that could influence results but are offset by resilient core operations.

QuidelOrtho (QDEL) held its Q2 2026 earnings call covering financial results, operational updates, and forward guidance. Earnings call delivers quarterly metrics and outlook that moderately influence near-term valuation and sentiment.

QuidelOrtho resets Q2 guidance amid China market headwinds and respiratory product uncertainty. Guidance reset amid China headwinds and respiratory uncertainty signals major shifts in QuidelOrtho's performance outlook.

QuidelOrtho (QDEL) stock drops sharply on weak results and lowered guidance that signal ongoing pressure in core diagnostics markets. Disappointing results and guidance cut create short-term pressure on valuation without fundamentally reshaping long-term trajectory.

QuidelOrtho beats Q2 earnings and revenue estimates but lowers 2026 guidance. Q2 beat offers limited upside while lowered 2026 guidance signals future growth concerns.

QuidelOrtho Corporation (QDEL) stock is positioned for reweighting towards peers amid deleveraging. Deleveraging enables peer-aligned reweighting with moderate effects on financial positioning.

QuidelOrtho Corporation held its Q2 2026 earnings call covering financial results, operational updates and forward outlook for the diagnostics company. Earnings call delivers standard quarterly financial and strategic details that moderately influence near-term investor views without indicating major shifts.

QuidelOrtho Corporation held its Q2 earnings call covering financial results, revenue figures, operational updates and forward outlook. Q2 earnings data and guidance directly affect near-term financial expectations and stock sentiment.

QuidelOrtho (QDEL) beat analyst estimates for both Q2 earnings and revenue. Quarterly earnings beat signals better-than-expected financial results and may lift near-term investor sentiment.

QuidelOrtho beat Q2 CY2026 sales expectations yet its stock fell 21.6%. Earnings beat paired with sharp stock drop signals moderate investor concern over outlook.

QuidelOrtho Corporation reported financial results for the second quarter of 2026. Quarterly earnings reports deliver performance data that can shift investor views on operations.

QuidelOrtho Corporation reported Q2 loss narrower than expected with revenues beating forecasts, pushing the stock higher. Positive Q2 earnings surprise supports near-term stock gains and sentiment without altering long-term trajectory.

QuidelOrtho exits an index and appoints a new CFO, signaling a possible shift away from prior growth strategy. Index exit combined with CFO change may alter investor visibility and strategic direction with moderate effects on operations and sentiment.

QuidelOrtho (QDEL) stock surges toward its best day in over a year as point-of-care sale talks ignite a rally. Point-of-care sale talks signal major strategic shift that could reshape QuidelOrtho's operations and market position.

QuidelOrtho Corporation's reliance on respiratory products continues to present a significant near-term risk to its financial performance and market position. Ongoing respiratory exposure creates moderate pressure on QuidelOrtho's near-term results and investor outlook without indicating transformative shifts.

Blood type incompatibilities between mother and fetus can cause severe complications including hemolytic disease, driving demand for accurate diagnostic testing in transfusion medicine and pregnancy monitoring. QuidelOrtho's immunohematology products directly address blood compatibility testing needs highlighted by pregnancy risks.

QuidelOrtho Corporation (QDEL) stock declined after Q1 earnings missed estimates and revenues fell year-over-year. Q1 earnings miss and year-over-year revenue decline directly harm financial performance and investor confidence.

QuidelOrtho Corporation released Q1 earnings call highlights covering financial results, revenue performance, operational updates, and forward guidance. Q1 earnings highlights detail financial metrics and guidance that significantly shape investor expectations and company trajectory.

QuidelOrtho Corporation released its Q1 2026 earnings call summary, detailing financial performance, operational updates, and forward guidance for the diagnostics firm. Q1 2026 earnings call summary discloses financial results and strategic outlook that significantly influence QuidelOrtho's stock trajectory and investor confidence.

QuidelOrtho Corporation (QDEL) released its Q1 2026 earnings call transcript. QDEL's Q1 2026 earnings transcript covers financial results, guidance, and strategy, poised to significantly sway investor sentiment and stock trajectory.

QuidelOrtho Corporation reported first quarter 2026 financial results. Quarterly earnings reports typically drive significant shifts in stock price and investor expectations for future performance.

QuidelOrtho Corporation (QDEL) reported a first-quarter loss but topped revenue estimates. Quarterly loss despite revenue beat signals moderate impact on financial performance and investor sentiment.

QuidelOrtho (NASDAQ:QDEL) missed Q1 CY2026 revenue estimates. Missing quarterly revenue estimates highlights financial underperformance likely to influence short-term investor sentiment and stock price.

QuidelOrtho Corporation (QDEL) will report earnings tomorrow, with analysts forecasting revenue of $697.4 million, down 17.5% year-over-year, EPS of -$1.20, and key focus on Labs and Transfusion Medicine segments amid ongoing restructuring. Upcoming earnings report and analyst expectations will moderately affect QDEL's financial performance and investor sentiment ahead of results.

QuidelOrtho (QDEL) Q1 earnings expected to decline. Expected Q1 earnings decline will moderately affect financial performance and investor sentiment.

Syphilis cases surge amid overlooked gaps in screening, diagnosis, and treatment; QuidelOrtho spotlights trends and pushes for advanced testing solutions. Rising syphilis prevalence boosts demand for diagnostics in QuidelOrtho's infectious disease portfolio without fundamentally altering overall trajectory.